UNSPSC 41181511: Beta-globulin immunological test system

In this classification, a Beta-globulin immunological test system is a device that consists of the reagents used to identify by immunochemical techniques Beta-globulin. US FDA regulates Beta-globulin immunological test system under 21 CFR 866.5160 and under FDA product code DCJ.

UNSPSC 41181511 Beta-globulin immunological test system is a Commodity code that shows little relevant recent activity. The recent opportunities tagged under this code span laboratory testing services, optical and photometric measurement equipment, software platforms for drug discovery and chemical modeling, electrical utility test boards and high-voltage measurement modules, spectrophotometers, wastewater treatment process instrumentation, and brake testing systems — none of which constitute beta-globulin immunological test systems or related serology platforms. The mismatch suggests either miscoding in the source opportunities or dormancy in active procurement under this specific code.

State and local governments issue few or no solicitations specifically for beta-globulin immunological test systems. The issuing bodies in the broader dataset include county governments (Collier County, Lee County Port Authority, Marion County), cities (Tampa, Phoenix, Ocala, Kissimmee, Orlando), universities (Valencia College, Jackson State University, Texas State University, Texas A&M University System), a state agency (Colorado State Patrol, Texas DSHS), a toll road authority (Harris County Toll Road Authority), and a municipal utility (Lubbock Power & Light). No issuing body appears more than once in connection with beta-globulin testing or immunology. The geographic spread covers Florida (Valencia College, Tampa, Kissimmee, Lee County, Collier County, Orlando), Texas (Jackson State University, Texas State University, Texas A&M System, DSHS Harlingen), Arizona (Phoenix), Colorado (State Patrol), and Oregon (Marion County), but these geographies reflect the broader laboratory and instrumentation activity, not beta-globulin-specific procurement. Without posted opportunities directly requesting beta-globulin immunological test systems or related assay platforms, the code does not support a viable pursue decision at this time.